N/A
N=61,864
Risk of Cancer Among Pantoprazole Users
Esophagitis
Bottom Line
View on ClinicalTrials.gov: NCT01322633 ↗Enrolled (actual)
61,864
Serious AEs
—
Results posted
Feb 2014
Primary outcome: Primary: Incidence Rate of Gastric Cancer — 19.88; 23.73 incidence per 100000 person-years
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Does not apply (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence Rate of Gastric Cancer |
19.88; 23.73 | — |
| SECONDARY Incidence Rate of Composite Gastrointestinal Cancers |
168.41; 129.25 | — |
| SECONDARY Incidence Rate of Overall Cancer |
1465.21; 1369.88 | — |
Summary
The primary objective is to assess whether the risk of gastric cancer is increased in pantoprazole users compared to users of other proton pump inhibitors.
Eligibility Criteria
Inclusion Criteria
- Patients who have used pantoprazole or other proton pump inhibitors, enrollment in the health maintenance organization for at least 6 months, age 18 years or older.
Exclusion Criteria
- Use of any proton pump inhibitor before study entry, any cancer diagnosis recorded in the medical history, diagnosis of Zollinger-Ellison Syndrome in medical history.
Data sourced from ClinicalTrials.gov (NCT01322633). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.